All In Biotech

Drug Trial Radar · NCT03025945

Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Last checked: Nov 20, 2026Latest source record: Dec 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 662 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

662

Actual

Start

Oct 2013

Primary completion

Jan 2017

Study completion Jan 2017

Sponsor

Lead sponsor
Intuor Technologies, Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

Conditions

  • Cystoid Macular Edema

Interventions

  • Nepafenac 0.3%Drug

  • Saline SolutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-operative Clinical Findings of Cystoid Macular EdemaTime frame: 6 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.